Roche Builds a Wide Moat With Dominant Oncology and Diagnostics Franchises
Firm has a promising strategy of combining expertise in both areas to generate a growing personalized medicine pipeline.
Following new immuno-oncology data at the ASCO meeting, we are maintaining our $33 billion estimate for annual IO drug sales by 2022 versus consensus expectations of $20 billion. While we continue to view Merck (MRK) as the most undervalued company in the IO group, we see Bristol as the best positioned in IO. Along with these companies, Roche and AstraZeneca (AZN) are also well entrenched in the important IO class, which should strengthen all of these companies' moats as IO drug demand should be high in several cancer settings that have unmet medical need along with strong drug pricing power ($150,000 annually).
While we are maintaining our long-term outlook for IO drugs, the composition of our estimates is shifting as the new data slightly weakens the outlook for the lung cancer indication and strengthens the outlook in the renal cancer indication.
Karen Andersen does not own (actual or beneficial) shares in any of the securities mentioned above. Find out about Morningstar’s editorial policies.
Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.
We’d like to share more about how we work and what drives our day-to-day business.
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.
How we use your information depends on the product and service that you use and your relationship with us. We may use it to:
To learn more about how we handle and protect your data, visit our privacy center.
Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.
To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.
Read our editorial policy to learn more about our process.